Molecular residual disease: Charting a new path for treating resectable solid tumors
- Author(s)
- Kobayashi, S; Hashimoto, T; Bando, H; Nakamura, Y; Parikh, A; Tie, J; Shi, Q; Oki, E; Yoshino, T;
- Details
- Publication Year 2026-09-14,Volume 44,Issue #9,Page 1715-1720
- Journal Title
- Cancer Cell
- Abstract
- Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenges conventional randomized designs. We propose an MRD Registry as an external control cohort that integrates quantitative ctDNA data with outcomes to validate ctDNA dynamics as response indicators-facilitating efficient MRD-based trial design and accelerating novel therapy development.
- Publisher
- Cell Press
- Keywords
- Humans; *Neoplasm, Residual/genetics; *Neoplasms/genetics/surgery/pathology/blood; *Circulating Tumor DNA/genetics/blood; *Biomarkers, Tumor/genetics/blood; Neoplasm Recurrence, Local/genetics
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 42735678
- Publisher's Version
- https://doi.org/10.1016/j.ccell.2026.08.001
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-10-02 08:18:58
Last Modified: 2026-10-02 08:19:08